Abonnez-vous à la Base de données d’Antiviral InteliStrat
Vous devez être abonné pour avoir accès à la Base de données (Database). Plusieurs options d’abonnement avec des coûts d’inscription variés sont disponibles tel que détaillé à la page Services.
L’échantillon ci-dessous montre le type d’information accessible à un abonné de la Base de données pour quelques produits typiques. Cela inclut aussi les Fiches détaillées des produits qui peuvent être visualisées en cliquant sur le nom des produits dans la grille.
Accéder à votre compte
Échantillon de la database
| Promoteur(s) | Produit | Type de produit | Mode d'action  |
Famille virale | Virus | Statut-1 | Statut-2 | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Sanofi (Sanofi Pasteur / Sanofi Aventis / Sanofi Genzyme) (global presence) | Dengvaxia Dengvaxia®; ChimeriVax-Dengue; ChimeriVax Dengue; CYD Dengue; CYD-TDV; CYD TDV |
Vaccine | Vaccine based on Recombinant, viral expression vector | Flaviviridae | Dengue virus (DENV) | Market / Licensed for use | Approved for market in Mexico (Dec. 2015), Philippines (Dec. 2015), Brazil (Dec. 2015), Salvador (Jan. 2016), EU (Dec. 19, 2018), USA (May 2019); Filings for marketing authorization completed in several countries endemic for Dengue Fever virus; See Rema | |||
|
Argos Therapeutics (formerly Merix Bioscience; USA) (now called CoImmune, no longer in antivirals) | AGS-004 AGS004; AGS 004; Arcelis |
Vaccine | Other | Retroviridae | HIV-1 (Human Immunodeficiency virus) | Phase II | 2 Phase II trials completed (2011 and 2015); No further development | |||
|
GSK (GlaxoSmithKline; Glaxo Wellcome) (global presence) | Retrovir® Zidovudine; Azidothymidine; AZT; BW A509U; Zydowin |
Inhibitor | RT Inhibitor: Nucleoside or Nucleotide (including NRTI, NRTTI and NcRTI Inhibitors) | Retroviridae | HIV-1 (Human Immunodeficiency virus) | Market / Licensed for use | Approved for market in US (Mar. 19, 1987) and other markets | |||
|
Pharmacor (acquired by Procyon/Ambrilia Biopharma; Canada) (no longer in operation) | P-1946 P1946; P 1946 |
Inhibitor | Protease Inhibitor (PI) | Retroviridae | HIV-1 (Human Immunodeficiency virus) | Preclinical | Lead compound | |||
|
TaiMed Biologics (Taiwan, USA) | Trogarzo™ Ibalizumab; Ibalizumab-uiyk; TNX-355; TNX355; TNX 355; Hu5A8; TMB-355; TMB355; TMB 355 |
Antibodies | Entry and/or Fusion inhibitor (single agent) | Retroviridae | HIV-1 (Human Immunodeficiency virus) | Market / Licensed for use | Orphan Drug status; Fast track status; Breakthrough Therapy Designation (Feb. 2015); Priority Review status granted by FDA (Jun. 2017), and FDA approval for US market granted on Mar. 06, 2018; Approved for EU market (Sep. 26, 2019); See Remarks | |||
|
Novartis (global) / Novartis Institutes for BioMedical Research (NIBR) / Novartis Institute for Tropical Diseases (NITD) | Focetria® Focetria® A(H1N1); Focetria A(H1N1); Focetria A/H1N1; Influenza A (H1N1) 2009 Monovalent Vaccine |
Vaccine | Non-recombinant protein (subunit) vaccine | Orthomyxoviridae | Swine Influenza virus | Market / Licensed for use | Approved by EMEA for distribution in EU (Sept. 29, 2009) under control of health authorities and governments; WHO-Prequalification status; No longer available (2015); See Remarks | |||
|
Abbott / AbbVie (global presence) | A-837093 A-837,093; A837093; A 837093 |
Inhibitor | RNA Polymerase Inhibitor | Flaviviridae | HCV (Hepatitis C virus) | Preclinical | No further development | |||
|
Abbott / AbbVie (global presence) | Paritaprevir Veruprevir; ABT-450; ABT450; ABT 450 |
Inhibitor | Protease Inhibitor (PI) | Flaviviridae | HCV (Hepatitis C virus) | Market / Licensed for use | Approved for market in US (Dec. 2014) and other markets as part of combination therapy called Viekira Pak; See Remarks | |||
|
Novavax (USA) (formerly DynCorp) | ResVax™ RSV-F VLP vaccine; RSV vaccine; RSV F-VLP vaccine; RSV F VLP vaccine; RSV F vaccine |
Vaccine | Recombinant protein (subunit) or nanoparticle/VLP vaccine | Pneumoviridae | RSV (Respiratory Syncytial virus) | Phase III | New Phase III initiated after failure of a first Phase III trial, Jan. 2017; Fast track designation granted by FDA (2016); See Remarks | |||
|
Johnson & Johnson Innovative Medicine / J&J Innovative Medicine (formerly Janssen Therapeutics) (global presence) | TMC353121 TMC-353121; TMC 353121 |
Inhibitor | Entry and/or Fusion inhibitor (single agent) | Pneumoviridae | RSV (Respiratory Syncytial virus) | Preclinical | No further development of the RSV program (Mar. 2023); See Remarks | |||
|
|||||||||||
